Every material Form 8-K NeuroPace Inc has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NeuroPace reported second quarter 2026 revenue of $22.8 million, up 17% from $19.5 million a year earlier, and its net loss narrowed to $6.2 million from $10.0 million. The company raised its full-year 2026 total revenue guidance and its Adjusted EBITDA loss outlook, which may matter to shareholders because it signals stronger expected sales and a smaller expected loss for the year.
Q2 2026 total revenue was $22.8 million, up 17% from $19.5 million in Q2 2025; RNS System revenue rose 21.3% to $22.5 million.
Q2 2026 net loss was $6.2 million, compared with $10.0 million in Q2 2025 (continuing operations).
Full-year 2026 total revenue guidance was raised to $99.5 million to $101.5 million from $99 million to $101 million.
Full-year 2026 Adjusted EBITDA guidance was raised to a loss of $7.5 million to $8.5 million from a loss of $8.5 million to $9.5 million.
NeuroPace received an FDA communication that its Premarket Approval Supplement to expand the RNS System indication to drug-resistant idiopathic generalized epilepsy is not approvable as submitted, and FDA has requested additional clinical evidence. The company says it will file a Submission Issue Request and amend the submission, and that its guidance does not include any contribution from the expanded indication.
FDA communication was received on the PMA-S target due date, and the company says it has begun working with FDA on the review team and a subsequent SIR meeting.
FDA requested additional clinical evidence from the NAUTILUS trial and literature supporting the submission.
At 18 months, patients treated with the RNS System had a 77% median reduction in GTC seizures from baseline, and 40% achieved GTC seizure freedom.
Full second quarter 2026 results and any full year outlook updates are scheduled for the August 11, 2026 earnings call.
NeuroPace reported first quarter 2026 results and raised its full-year 2026 revenue guidance to $99 million to $101 million, up from $98 million to $100 million. Revenue excluding DIXI Medical grew 20.1% year over year to $22.0 million, while GAAP revenue was $22.1 million compared with $22.5 million a year earlier. The GAAP net loss was $6.7 million, slightly wider than the $6.6 million loss in the first quarter of 2025, and cash and equivalents fell to $54.8 million from $61.2 million at the prior quarter end.
Q1 2026 revenue excluding DIXI Medical was $22.0 million, up 20.1% year over year; RNS System revenue was $21.7 million, up 19.5%.
Full-year 2026 revenue guidance raised to $99 million to $101 million; Adjusted EBITDA loss guidance narrowed to ($8.5) million to ($9.5) million from ($9.0) million to ($10.0) million.
GAAP net loss was $6.7 million in Q1 2026 versus $6.6 million in Q1 2025.
DIXI Medical will be reported as discontinued operations beginning with the second quarter 2026 results.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NeuroPace Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →